Board of Directors

David F. Hale, Executive Chairman, SkinMedica, Inc., Chairman, Hale Biopharma Ventures

David F. Hale has been a member of the Board of Directors since 2001 and Chairman of the Board since March 2003. He has been Executive Chairman since May 2006. Mr. Hale has had a significant career in the biopharmaceutical industry, most recently serving as President and CEO of CancerVax Corporation until its merger with Micromet, Inc. in May 2006, when he assumed the role of Chairman of the combined company. He previously served as President and CEO of Women First HealthCare, Inc. from January 1998 to May 2000, and as founding CEO, President and Chairman of Gensia, Inc., a biopharmaceutical company which acquired Sicor in 1996 to form Gensia Sicor. Gensia Sicor, in 2004, was sold to Teva Pharmaceutical Industries, Ltd. Prior to Gensia, Hale was President and CEO of a biotechnology company, Hybritech, the first monoclonal antibody company, which was sold to Eli Lilly and Co. in 1986. Mr. Hale previously held sales, marketing and general management positions with Johnson & Johnson and Becton Dickinson and Co. Hale is a co-founder and Chairman of Somaxon Pharmaceuticals, co-founder and a Director of Verus Pharmaceuticals and Zogenix, Inc., serves as Chairman of Santarus, Inc., and is a Director of Metabasis Therapeutics, Inc. Mr. Hale is also a co-founder and a Director of BIOCOM, the California Healthcare Institute and CONNECT. He serves on the Board of Directors of the Biotechnology Industry Organization, The Rady Children's Hospital and Health Center, the Burnham Institute and the San Diego Economic Development Corporation.

Graham D.S. Anderson, General Partner, EuclidSR Partners

Graham D. S. Anderson has been a member of our board of directors since March 2005. Mr. Anderson has been a general partner of EuclidSR Partners, a venture capital fund management firm, since 1996. From 1995 to 1996, he was with Salzinger & Company, a management consulting firm, where he served as a management consultant to America Online's Greenhouse Project, Image Technology Corporation (now network MCI Digital Imaging), CI Impressions and The Walt Disney Company. Prior to joining Salzinger & Company, Mr. Anderson practiced law at Susman Godfrey in Houston, Texas where he concentrated on securities, private equity and software law. Mr. Anderson also serves as a director of several private companies. Mr. Anderson received a Bachelor of Arts degree in Classics and a Juris Doctor degree from Yale University and a Master of Philosophy from the University of Glasgow.

Mary Fisher, Chief Executive Officer, SkinMedica, Inc.

Mary Fisher joined SkinMedica as Chief Executive Officer, and a member of the Board of Directors, in April 2008. Ms. Fisher's previous experience includes more than 25 years in the pharmaceutical and biotechnology industries. Most recently, she was Chief Operating Officer of Acorda Therapeutics, a CNS company, with responsibility for corporate strategy and business development, financial planning, sales and marketing, and manufacturing. Previously, Ms. Fisher was VP, Strategic Healthcare and Commercial Operations for Cephalon, with responsibility for product planning and marketing, managed care sales, and manufacturing. Her earlier experience includes positions at Immunex and Boehringer Ingelheim. She is also a member of the Board of the Neuroscience Nursing Foundation.

Rex Bright, President, SkinMedica, Inc.

Rex Bright has served as our President and a member of our board of directors since January 2002. Mr. Bright's previous career included 18 years at Johnson & Johnson and six years as president of Allergan's dermatology business. During his tenure at J&J, Mr. Bright headed up Ortho-McNeil's dermatology division which included Retin-A and other prescription pharmaceutical products for the treatment of dermatological diseases. Subsequent to his tenure at Allergan he founded several start-up companies, and spent approximately seven years in the Boston area completing workout and turnaround assignments, as an interim CEO, for small private and public health care companies.

Mr. Bright is a member of Vistage International, the North American Clinical Dermatology Society and the American Academy of Dermatology. He serves on the board of BIOCOM, the southern California biotechnology and pharmaceutical industry association. He received a Bachelor of Arts degree in Business Administration and Marketing from Drury University in Springfield, Missouri.

James Cavanaugh, Ph.D., Managing Director, HealthCare Ventures LLC

James H. Cavanaugh, Ph.D. has been a managing director of HealthCare Ventures since 1989. He was previously president of SmithKline & French Laboratories-U.S., the domestic pharmaceutical division of SmithKline Beckman Corporation. He had been president of SmithKline Beckman's clinical laboratory business and President of Allergan International. He served as staff assistant to President Nixon for Health Affairs and then deputy director of the President's Domestic Council. Under President Ford, he was a deputy assistant to the President for domestic affairs and deputy chief of the White House. He has served as deputy assistant secretary for health and scientific affairs in the United States Department of Health, Education and Welfare, special assistant to the Surgeon General, United States Public Health Services, and director, Office of Comprehensive Health Planning. He began his career as a member of the faculty of the Graduate College and the College of Medicine at the University of Iowa where he received his master's and doctorate degrees.

Brian H. Dovey, General Partner, Domain Associates LLC 

Brian H. Dovey has been a member of our board of directors since November 2002. He has been a General Partner of Domain Associates, LLC, a venture capital firm, since 1988. In 1983, Mr. Dovey joined Rorer Group, Inc. (now Sanofi-Aventis), a pharmaceutical company, and was the President of Rorer from 1986 to 1988. Previously, Mr. Dovey was President of Survival Technology, Inc., a biotechnology company, from 1972 to 1986, and has also held management positions with Howmedica, Inc., an orthopedic company, from 1967 to 1971. He serves on the Board of Directors of Align Technology, Cardiac Science, Neose Technologies, Inc., as well as several private companies. He received a Bachelor of Arts degree from Colgate University and a Masters of Business Administration degree from Harvard Business School. 

Richard E. Fitzpatrick, M.D., Founder, Chairman, Scientific Advisory Board, SkinMedica, Inc.

Richard E. Fitzpatrick, M.D., is one of our founders and has been a member of our board of directors since our inception in May 1999. He also serves as Chairman of our Scientific Advisory Board. Dr. Fitzpatrick has been in private practice in San Diego since 1978 and has been an Assistant or Associate Clinical Professor in the Division of Dermatology at UCSD School of Medicine since 1982. He is a Fellow of the American Board of Dermatology and the American Society of Dematologic Surgery, a member of the American Academy of Facial Plastic and Cosmetic Surgery and the former President of the American Society of Laser Medicine and Surgery. Dr. Fitzpatrick received a Bachelor of Arts degree in Biology from Princeton University and a Doctorate of Medicine degree from Emory University Medical School.

Adele C. Oliva, Partner, Apax Partners

Adele C. Oliva has been a member of our Board of Directors since May 2005.  Ms. Oliva is a partner at Apax Partners specializing in the health care industry with a focus on the specialty pharmaceuticals and medical-device sectors. An advisor to a number of health care companies, Adele brings experience in both the investment, marketing and business development issues facing companies in this industry. Most recently, Adele led Apax Partners' investment and exit in ESP Pharma, a specialty pharmaceutical company dedicated to improving patient survival in the acute-care setting. Adele joined Apax Partners in 1997, having been awarded the prestigious Ewing Marion Kauffman Fellowship in venture capital and entrepreneurship. Previously, she held positions in marketing and business development with Baxter Healthcare in the company's CardioVascualr and I.V. Systems divisions. Adele's experience also includes positions with Ogilvy & Mather where she was employed in the firm's office in Hungary, and with CoreStates Financial Corp., where she worked as a commercial lending officer and senior financial analyst. Adele is a graduate of Saint Joseph's University and earned an MBA from Cornell University, where she was awarded a Fried Fellowship.

William A. Roper, Jr., President & CEO, VeriSign Inc.

William A. Roper, Jr. has been a member of our board of directors since January 2002. Since 2007, he has been the President & CEO of VeriSign, Inc., an infrastructure and global networking services company. Previously, he was with Science Applications International Corporation, or SAIC, a research and engineering company. While there, Mr. Roper served as the Company’s Chief Financial Officer and, in October 2000, he became Chairman of the Board of SAIC Venture Capital Corporation. From 1987 to 1990, Mr. Roper served as Executive Vice President and Chief Financial Officer of Intelogic Trace, Inc., a technology company. From 1981 to 1987, Mr. Roper served in several capacities with Bell & Howell Company, a technology company, including Corporate Vice President and Treasurer. Mr. Roper currently serves as a director of Regents Bank, NA. Mr. Roper received a Bachelor of Arts in Mathematics from the University of Mississippi, a graduate degree from Southwestern Graduate School of Banking at Southern Methodist University and a degree from Stanford University's Financial Management Program.

Andrew N. Schiff, M.D., Managing Director, Perseus-Soros Biopharmaceutical Fund

Andrew N. Schiff, M.D., has been a member of our board of directors since February 2004. Dr. Schiff joined Perseus-Soros Management, LLC, an affiliate of Perseus-Soros BioPharmaceutical Fund, LP, a private equity firm, in September of 1999 and currently serves as a Managing Director. Over the last 10 years, Dr. Schiff has practiced internal medicine at The New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. He currently serves as a director of several biotechnology companies, including Bioenvision, Inc., Myogen, Inc., Barrier Therapeutics, Inc. and Adams Respiratory Therapeutics, Inc. Dr. Schiff received a Bachelor of Science in Neuroscience with honors from Brown University, a Doctorate of Medicine degree from Cornell University Medical College and a Master of Business Administration degree from Columbia University.